Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Carly Kenselaar has maintained a Buy rating on Travere Therapeutics and raised the price target from $14 to $23.
September 06, 2024 | 6:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup has increased its price target for Travere Therapeutics from $14 to $23, maintaining a Buy rating. This suggests a positive outlook for the company's stock.
The increase in price target from $14 to $23 by Citigroup indicates a strong positive sentiment towards Travere Therapeutics. Maintaining a Buy rating suggests confidence in the company's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100